Drug Profile
Research programme: monoclonal antibody therapeutics - Celldex Therapeutics Inc/Takeda
Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Dyax; Kolltan Pharmaceuticals
- Developer Celldex Therapeutics Inc; Dyax
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 29 Nov 2016 Kolltan Pharmaceuticals has been acquired and merged into Celldex Therapeutics
- 01 Aug 2013 No development reported - Preclinical for Cancer in USA (Parenteral)